Pyrazinamide

Spécifications

98-96-4Numéro CAS

202-717-6Numéro CE

pyrazine-2-carboxamideNom IUPAC

C5H5N3OFormule chimique

123.11 g/molMasse molaire

pyrazinamide; pyrazinecarboxamide; 98-96-4; pyrazine-2-carboxamide; Aldinamide; Zinamide; pyrazinoic acid amide; Aldinamid; Farmizina; Pirazimida; Pirazinamid; Unipyranamide; Eprazin; Novamid; Tebrazid; Pyrafat; pyrazine carboxylamide; Pyrazineamide; Isopas; 2-Carbamylpyrazine; Pyrazinecarboxylic acid amide; Pirazinamida; Pyrazinamidum; Pyrazide; Rozide; Pirazinamide; Pyrazine carboxamide; pyramizade; MK 56; NCI-C01785; DTXSID9021215; MK-56; 2KNI5N06TI; NSC-14911; NSC14911; pyrazine-2-carboximidic acid; DTXCID801215; CHEBI:45285; 5-25-04-00178 (Beilstein Handbook Reference); alpha-pyrazinamide; pyrazinamide tablet; RefChem:6182; J04AK01; 202-717-6; Pirilene; 2-Pyrazinecarboxamide; D-50; PZA; MFCD00006132; NSC 14911; .alpha.-pyrazinamide; Tisamid; T 165; MLS000069730; Piraldina; Pyrazinamide (Pyrazinoic acid amide); s1762; NCGC00015833-09; Pyrazinamdie; Pezetamid; SMR000036662; Pirazinamide [DCIT]; Pyrazinamidum [INN-Latin]; Pirazinamida [INN-Spanish]; Rifafour; D-50 (VAN); DRG 0124; CAS-98-96-4; CCRIS 545; Rifafour e-200; HSDB 3576; SR-01000076077; EINECS 202-717-6; UNII-2KNI5N06TI; BRN 0112306; pyrazinamida; Pyrizinamide; pyrazine amide; Pyrazinamide RS; Pyrazinamide CRS; Pyrazine-2-carboxylic acid amide; Pirazinecarboxamide; Pyrazinamide [USP:INN:BAN:JAN]; Prestwick_811; 2-pyrazine carboxamide; Spectrum_000902; Pyrazinamide (Standard); Opera_ID_735; pyrazine, 2-carbamoyl-; Prestwick0_000514; Prestwick1_000514; Prestwick2_000514; Prestwick3_000514; Spectrum2_001305; Spectrum3_001046; Spectrum4_001186; Spectrum5_001026; Lopac-P-7136; PYRAZINAMIDE [MI]; PYRAZINAMIDE [INN]; PYRAZINAMIDE [JAN]; CHEMBL614; P 7136; PYRAZINAMIDE [HSDB]; WLN: T6N DNJ BVZ; PYRAZINAMIDE [VANDF]; Lopac0_001011; SCHEMBL24102; BSPBio_000467; BSPBio_002572; KBioGR_001851; KBioSS_001382; PYRAZINAMIDE [MART.]; MLS002222347; BIDD:GT0228; DivK1c_000241; PYRAZINAMIDE [USP-RS]; PYRAZINAMIDE [WHO-DD]; PYRAZINAMIDE [WHO-IP]; SCHEMBL733102; SCHEMBL956745; SPECTRUM1500518; SPBio_001369; SPBio_002388; BPBio1_000515; GTPL7287; orb1223474; orb1308657; orb3025148; SCHEMBL2438217; SCHEMBL4931800; SCHEMBL29408106; HMS500M03; HY-B0271R; KBio1_000241; KBio2_001382; KBio2_003950; KBio2_006518; KBio3_001792; Pyrazinamide (JP18/USP/INN); NINDS_000241; BDBM228814; HMS1569H09; HMS1920N08; HMS2092E09; HMS2096H09; HMS2235G17; HMS3259O04; HMS3263K03; HMS3371G09; HMS3655A10; HMS3713H09; HMS5080I03; KUC109577N; Pharmakon1600-01500518; PYRAZINAMIDE [ORANGE BOOK]; PYRAZINAMIDE [EP MONOGRAPH]; PYRAZINAMIDE [USP IMPURITY]; ALBB-038645; HY-B0271; KSC-27-052E; WZB81781; PYRAZINAMIDE [USP MONOGRAPH]; Tox21_110237; Tox21_202059; Tox21_302771; Tox21_501011; CCG-39243; EBC-03189; MSK000777; NSC757304; PYRAZINAMIDUM [WHO-IP LATIN]; RIFATER COMPONENT PYRAZINAMIDE; SBB004276; STK801661; AKOS000120280; Tox21_110237_1; AP27270; DB00339; LP01011; NC00534; NSC-757304; Pyrazinecarboxamide, analytical standard; SDCCGSBI-0050984.P005; IDI1_000241; NCGC00015833-01; NCGC00015833-02; NCGC00015833-03; NCGC00015833-04; NCGC00015833-05; NCGC00015833-06; NCGC00015833-07; NCGC00015833-08; NCGC00015833-10; NCGC00015833-11; NCGC00015833-12; NCGC00015833-15; NCGC00015833-16; NCGC00015833-21; NCGC00015833-25; NCGC00090695-01; NCGC00090695-03; NCGC00090695-04; NCGC00090695-05; NCGC00090695-06; NCGC00090695-07; NCGC00256336-01; NCGC00259608-01; NCGC00261696-01; Pyrazinoic acid amide; pyrazinamide; PZA; CAS- 98-96-4; SY013550; TS-01626; SBI-0050984.P004; DB-002866; AB00052083; EU-0101011; NS00010008; P0633; P9671; ST45022155; SW196945-3; EN300-15621; C01956; D00144; D70481; AB00052083-16; AB00052083_17; AB00052083_18; AC-907/25014068; F068696; Q417571; SR-01000076077-1; SR-01000076077-4; SR-01000076077-6; BRD-K28667793-001-27-3; BRD-K28667793-001-28-1; Z33546644; Pyrazinamide, British Pharmacopoeia (BP) Reference Standard; Pyrazinamide, European Pharmacopoeia (EP) Reference Standard; Pyrazinamide, United States Pharmacopeia (USP) Reference Standard; InChI=1/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9; Pyrazinamide, Pharmaceutical Secondary Standard; Certified Reference MaterialSynonymes